ITMN
{"sector":"Healthcare","industry":"Drugs","symbol":"ITMN","company_name":"InterMune","exchange":"NASDAQ"}ITMN Articles
These are the top analyst upgrades and downgrades from 24/7 Wall St. for Tuesday, August 26, 2014.
Published:
These are the top analyst upgrades and downgrades from 24/7 Wall St. for Monday, August 25, 2014.
Published:
These are the top analyst upgrades and downgrades from 24/7 Wall St. for Thursday, August 21, 2014. They include Hewlett-Packard, InterMune, MeetMe, Target and Tesla Motors.
Published:
Jon OggStocks were very strong on Thursday morning. Investors have been using the recent weakness and volatility to accumulate some stocks they may have previously missed. 24/7 Wall St. reviews...
Published:
A new report from the analysts at Cowen shows that, on average, biotech stocks gained 84% in the 12 months prior to an FDA approval and lost 24% in the 12 months after the approval.
Published:
Here are the four top biotech names we found that all have hepatitis C drugs in their current pipelines at one stage or another and that could be the next takeover targets.
Published:
ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index and...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, March 11, 2014. They include AMD, Apple, CDW, Facebook and J.C. Penney.
Published:
Jon OggThe higher the market goes, the more likely analysts are to pull the trigger on names they think are stretched. The problem for analysts: In a hot market, stocks often go higher when they are...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on the final day of February 2014. The include Deckers Outdoor, InterMune, MarkWest Energy...
Published:
thinkstockFebruary 25, 2014: Markets opened slightly higher on Tuesday then bounced around the break-even line right up until the closing bell. Consumer goods, materials, and services tried to keep...
Published:
Last Updated:
ThinkstockShares of biotech company InterMune Inc. (NASDAQ: ITMN) more than doubled Tuesday after the company said its experimental drug pirfenidone, in a late-stage trial, reduced the progression of...
Published:
ThinkstockMost of the major mega cap biotechnology companies have reported earnings and the results almost across the board have been very good. The problem for many investors is many of the top...
Published:
Teva Pharmaceutical resume a deal-making strategy that made it one of the most acquisitive drug companies of the past decade. Could one of these biotech takeover candidates be the next target?
Published:
The analysts at UBS are not only bullish on the biotechnology sector, they think there is a very distinct possibility that some of the top names may also become takeover targets this year.
Published: